YD Bio Ltd
Business
YD Bio Ltd is a publicly listed biotechnology company focused on regulated diagnostics, life science clinical services, and healthcare product commercialization. The company operates DNA methylation-based oncology testing programs for pancreatic and breast cancers under a laboratory-developed test (LDT) framework through CLIA-certified laboratory partners, provides regulated life science distribution and clinical trial supply chain services to pharmaceutical companies, and develops exosome-based eye disease therapeutics and contact lens products. YD Bio serves pharmaceutical and biotechnology clients in the United States and Asia through partnerships and its own distribution channels.
Summary from 20-F filed 2026-04-30
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | $596.8K |
| Net income | $-8.31M |
| Total assets | $13.78M |
| Total liabilities | $16.64M |
| Stockholders' equity | $-2.86M |
| Operating cash flow | $-6.60M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is YD Bio Ltd's CIK number?
YD Bio Ltd's SEC CIK number is 0002011674 (2011674). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find YD Bio Ltd's SEC filings?
All of YD Bio Ltd's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.